Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/28728
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorVELLOSO, Elvira Deolinda Rodrigues Pereira
dc.contributor.authorMAGALHÃES, Silvia Maria Meira
dc.contributor.authorCHAUFFAILLE, Maria de Lourdes Lopes Ferrari
dc.contributor.authorBUZZINI, Renata
dc.contributor.authorBERNARDO, Wanderley Marques
dc.date.accessioned2018-10-11T19:03:48Z
dc.date.available2018-10-11T19:03:48Z
dc.date.issued2018
dc.identifier.citationHEMATOLOGY, TRANSFUSION AND CELL THERAPY, v.40, n.3, p.267-273, 2018
dc.identifier.issn2531-1379
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/28728
dc.language.isoeng
dc.publisherAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.relation.ispartofHematology, Transfusion and Cell Therapy
dc.rightsopenAccess
dc.titlePart 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
dc.typearticle
dc.rights.holderCopyright Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
dc.identifier.doi10.1016/j.htct.2018.05.011
dc.identifier.pmid30128437
dc.subject.wosMedicine, General & Internal
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
hcfmusp.author.externalMAGALHÃES, Silvia Maria Meira:Universidade Federal do Ceará, Brazil
hcfmusp.author.externalCHAUFFAILLE, Maria de Lourdes Lopes Ferrari:Grupo Fleury, Brazil; Universidade Federal de São Paulo, Brazil
hcfmusp.author.externalBUZZINI, Renata:Associação Médica Brasileira, Brazil
hcfmusp.description.beginpage267
hcfmusp.description.endpage273
hcfmusp.description.issue3
hcfmusp.description.volume40
hcfmusp.origemWOS
hcfmusp.origem.idSCIELO:S2531-13792018000300267
hcfmusp.origem.id2-s2.0-85050853215
hcfmusp.origem.idWOS:000587465200013
hcfmusp.relation.referenceBalleari E, 2006, ANN HEMATOL, V85, P174, DOI 10.1007/s00277-005-0044-6
hcfmusp.relation.referenceBalleari E, 2011, LEUKEMIA RES, V35, P1472, DOI 10.1016/j.leukres.2011.05.025
hcfmusp.relation.referenceCastelli R, 2014, ANN HEMATOL, V93, P1523, DOI 10.1007/s00277-014-2070-8
hcfmusp.relation.referenceChung CY, 2012, ANTICANCER RES, V32, P3415
hcfmusp.relation.referenceFili C, 2013, CLIN CANCER RES, V19, P3297, DOI 10.1158/1078-0432.CCR-12-3540
hcfmusp.relation.referenceGarcia-Manero G, 2013, J CLIN ONCOL, V31, P2548, DOI 10.1200/JCO.2012.44.6823
hcfmusp.relation.referenceGattermann N, 2012, EUR J HAEMATOL, V88, P260, DOI 10.1111/j.1600-0609.2011.01726.x
hcfmusp.relation.referenceGoldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018
hcfmusp.relation.referenceGreenberg PL, 2013, LEUKEMIA LYMPHOMA, V54, P321, DOI 10.3109/10428194.2012.713477
hcfmusp.relation.referenceHata T, 2013, INT J HEMATOL, V98, P687, DOI 10.1007/s12185-013-1468-8
hcfmusp.relation.referenceHellstrom-Lindberg E, 2003, BRIT J HAEMATOL, V120, P1037, DOI 10.1046/j.1365-2141.2003.04153.x
hcfmusp.relation.referenceHellstromLindberg E, 1997, BRIT J HAEMATOL, V99, P344, DOI 10.1046/j.1365-2141.1997.4013211.x
hcfmusp.relation.referenceKelaidi C, 2013, ANN HEMATOL, V92, P621, DOI 10.1007/s00277-013-1686-4
hcfmusp.relation.referenceKim IH, 2015, TRANSFUSION, V55, P1613, DOI 10.1111/trf.13036
hcfmusp.relation.referenceLi X, 2012, AM J HEMATOL, V87, P26, DOI 10.1002/ajh.22184
hcfmusp.relation.referenceLian XY, 2016, PLoS ONE, V11
hcfmusp.relation.referenceList A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668
hcfmusp.relation.referenceList AF, 2012, J CLIN ONCOL, V30, P2134, DOI 10.1200/JCO.2010.34.1222
hcfmusp.relation.referenceMainous AG, 2014, BRIT J HAEMATOL, V167, P720, DOI 10.1111/bjh.13053
hcfmusp.relation.referenceMannone L, 2006, BRIT J HAEMATOL, V133, P513, DOI 10.1111/j.1365-2141.2006.06070.x
hcfmusp.relation.referenceMeerpohl JJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007461.pub3
hcfmusp.relation.referenceMoyo V, 2008, ANN HEMATOL, V87, P527, DOI 10.1007/s00277-008-0450-7
hcfmusp.relation.referenceMusto P, 2005, BRIT J HAEMATOL, V128, P204, DOI 10.1111/j.1365-2141.2004.05288.x
hcfmusp.relation.referenceMusto P, 2010, LEUKEMIA RES, V34, P981, DOI 10.1016/j.leukres.2009.10.022
hcfmusp.relation.referenceMusto P, 2010, CANCER-AM CANCER SOC, V116, P1485, DOI 10.1002/cncr.24894
hcfmusp.relation.referenceOliva EN, 2017, LANCET HAEMATOL, V4, pE127, DOI 10.1016/S2352-3026(17)30012-1
hcfmusp.relation.referencePark S, 2016, BRIT J HAEMATOL, V174, P730, DOI 10.1111/bjh.14116
hcfmusp.relation.referenceRaza A, 2008, BLOOD, V111, P86, DOI 10.1182/blood-2007-01-068833
hcfmusp.relation.referenceSanchez-Garcia J, 2015, LEUKEMIA RES, V39, pS59, DOI 10.1016/S0145-2126(15)30115-6
hcfmusp.relation.referenceSantini V, 2016, J CLIN ONCOL, V34, P2988, DOI 10.1200/JCO.2015.66.0118
hcfmusp.relation.referenceTobiasson M, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.8
hcfmusp.relation.referenceToma A, 2016, LEUKEMIA, V30, P897, DOI 10.1038/leu.2015.296
hcfmusp.relation.referenceLevels of Evidence and Grades of Recommendations, Oxford Centre for Evidence Based Medicine
dc.description.indexWoS
hcfmusp.citation.scopus1
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM


Files in This Item:
File Description SizeFormat 
art_VELLOSO_Part_3_Myelodysplastic_syndromes—Treatment_of_lowrisk_patients_without_2018.PDFpublishedVersion (English)336.08 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.